Wikipedia
Risankizumab
Risankizumab also known as BI-655066 is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. The therapeutic potential of risankizumab is being evaluated in immunological disorders, including Crohn's disease, psoriasis, psoriatic arthritis, and asthma. It is currently in phase II clinical drug trials for Crohn's disease, psoriatic arthritis, and asthma; it is in phase III clinical drug trials for psoriasis.